Health Dashboard — Shaun

Clinical Synthesis & Recommendations

1. Diet & Metabolic

Body fat 29.2% (target <24%), visceral fat index 19.4 (threshold ≥15 = very high), waist 107 cm (European threshold 102 cm — exceeded), weight 91.9 kg, LBM 61.7 kg. BMR 1,886 kcal · TDEE 2,593 kcal. At 500 kcal/day deficit, estimated time to ≤24% body fat: ~2 months.

• Target ~2,094 kcal/day — 500 kcal below TDEE. Keep the deficit modest: with a BED diagnosis, aggressive restriction reliably triggers rebound cycles that exceed the deficit.
• Protein 100–130 g/day (1.6–2.1 g/kg LBM) — the single most evidence-backed intervention for preserving lean mass during fat loss.
• Reduce refined carbohydrates and added sugar — insulin suppression preferentially mobilises the visceral depot; Mediterranean pattern for cardiovascular and renal protection (eGFR 78).
• No meals after 21:00 — late eating elevates sleeping HR and WASO in this dataset.
• Alcohol: eliminate during sleep-recovery focus periods — each drink adds ~15 min WASO (personal estimate); even one drink meaningfully suppresses deep sleep.
• Creatine supplement ⚠ — always declare at blood panels; it artificially elevates serum creatinine and can mask the declining eGFR trend (78, down from 121 over 4 years). Do not stop creatine; just flag it.
• Omega-3 2000 mg (already in stack) supports lipids (LDL 78, HDL 65 — currently healthy) and systemic inflammation; keep it. Magnesium 300 mg after dinner supports sleep onset via GABA-ergic pathways.

2. Activity

30-day step average: 8,923/day — near or above 8,700-step baseline. Visceral fat responds preferentially to aerobic volume. Given RMSSD at 23.2 ms, prioritise sustained low-intensity movement over high-intensity training while autonomic load is elevated.

• Walk to 10,000–11,000 steps/day — break radiology reporting sessions every 45–60 min, take stairs, walk to lunch. Highest-leverage, zero-equipment intervention for visceral fat.
• Resistance training 2× per week (compound movements: squat, hinge, push, pull) — non-negotiable for preserving LBM (61.7 kg) during fat loss; also directly improves insulin sensitivity.
• Zone 2 only while RMSSD <30 ms — high-intensity cardio at current autonomic baseline spikes cortisol and blunts fat oxidation. Brisk walking, cycling, or swimming at conversational pace is sufficient and safer.
• Yoga or mobility 2× per week — well-tolerated at any RMSSD level; supports HRV recovery and reduces musculoskeletal stiffness from desk work.
• Schedule intense sessions in the morning on work days — post-exercise sleeping HR elevation lasts ~18–24h; afternoon gym raises overnight HR and distorts recovery data.
• ADHD-compatible habit design — attach exercise to an existing daily anchor (shift start, post-meal) rather than scheduling it as a standalone event; three concrete rules outperform ten intentions.

3. Sleep Hygiene

30-day WASO: 44 min/night (within 23–50 band). Average TST: 6h27m. Zolpidem taper ongoing (2025-09-01 → est. 2026-11-01). Awakenings will rise transiently at each dose step — this is pharmacological rebound, not clinical failure. TST duration is weakly predictive of HRV in this dataset (r≈0.006 with next-day RMSSD); fragmentation (WASO) is the primary lever.

• Fixed wake time ±30 min, 7 days/week — the strongest single circadian anchor. Do not compensate for a poor night by sleeping in; this delays the circadian phase and worsens the next night.
• Bedroom ≤19°C — reduces spontaneous arousals and promotes slow-wave onset; core body temperature drop is a sleep-onset trigger.
• Screens off by 21:30 — the cognitive activation effect (scrolling, notifications) is larger than the blue-light melatonin effect; eliminate both.
• Caffeine cutoff 13:00 — half-life 5–7 hours; afternoon coffee is in bloodstream at 22:00 and elevates arousal threshold through the first half of sleep.
• Zolpidem taper sequence (drops formulation): Transition (25 drops, 10 mg) → Step 1 (19 drops, 7.5 mg) → Step 2 (13 drops, 5 mg) → Step 3 (6–7 drops, 2.5 mg). Raise with Nadia at next appointment; allow 2–3 stable weeks per step before reducing further.
• Expect 1–2 weeks rebound per dose step — increased awakenings during the transition week are expected; do not interpret as taper failure or escalate the dose.
• Sleep restriction therapy is the evidence-based next step if WASO remains >50 min after taper settles (~late 2026). Requires working with a sleep specialist or structured CBT-I protocol.

4. Autonomic Recovery & Meditation

Sleeping HR 30d avg 70.8 bpm (band 59–72, baseline 65). Samsung sleep HRV 30d avg 41.5 ms — within 37–62 band — note this signal is pharmacologically confounded by Zolpidem until ~November 2026. HRV4Training morning RMSSD (23.2 ms) is the primary autonomic metric for the taper period. Meditation baseline: 2026-06-21.

• Daily meditation 15–20 min — 6–8 weeks of consistent daily practice produces +3–8 ms RMSSD improvement on average in sedentary adults (Meland 2020). Sleeping HR typically drops 2–4 bpm within 4 weeks.
• Resonance breathing (4–6 breaths/min) during sessions — a direct parasympathetic driver; increases respiratory sinus arrhythmia and is the mechanism through which meditation raises RMSSD.
• Track RMSSD in HRV4Training every morning before coffee — watch for it trending consistently >30 ms as a milestone. Review the wellbeing subscores (fatigue, mental energy, muscle soreness) weekly for subjective-objective discordance.
• Subjective-objective discordance warning — if RMSSD is high but fatigue or mental energy scores are low for >3 consecutive days, reduce training load; this pattern is an early overreaching signal.
• Samsung sleep HRV (shrv) will re-establish post-taper — do not draw autonomic conclusions from shrv until ~December 2026. Use HRV4Training RMSSD as the single source of truth until then.
• Respiratory rate 15.1/min (baseline 14.3, band 13.5–15.2) — elevations >15.5/min without illness are an autonomic load signal; slow breathing during meditation directly addresses this.

5. Long-Term Vision

Most recent BP 128/75 mmHg — within target (<130/80). The four interacting risk drivers (visceral fat, sleep fragmentation, low activity volume, cardiovascular load) form a bidirectional causal loop: poor sleep → raised cortisol → visceral fat deposition → worsened sleep quality → higher cortisol. Family history amplifies urgency: paternal diabetes (grandmother, great-uncle), paternal hypertension (father, grandfather), maternal depression. 12-month targets: visceral fat index <13, body fat <24%, sleeping HR <65 bpm, RMSSD trending upward from current baseline.

• Breaking the cortisol loop via WASO reduction is faster than diet alone for visceral fat — the two reinforce each other and must be tackled simultaneously.
• eGFR 78, declining trend (121→118→116→91→78, 2022–2026) — annual monitoring is mandatory. Maintain hydration, avoid NSAIDs and nephrotoxic supplements, declare creatine at every panel. If eGFR falls below 60, formal nephrology referral.
• Waist circumference 107 cm (European threshold 102 cm) — re-measure every 4–6 weeks as a leading indicator of visceral fat change, complementary to scale weight.
• Glucose 94 mg/dL — close to the 100 mg/dL pre-diabetes threshold, given paternal DM family history. Visceral fat reduction is the primary intervention; request HbA1c at next panel.
• BED management integration — any dietary plan must avoid triggering the restriction-rebound cycle; frame caloric targets as "fuel to sustain the deficit" not "eat less." Consider structured support if patterns persist.
• Psychiatric stability is a prerequisite for metabolic change — do not layer aggressive dietary restriction or high-intensity training during Zolpidem taper transitions. Let each step settle before increasing metabolic demand.
• Lipids currently healthy (LDL 78, HDL 65, ratio 2.4, cholesterol 160) — Omega-3 2000 mg + Mediterranean pattern maintains this without statins; recheck annually given family history.
• ADHD-compatible long-term design — three concrete daily rules with immediate feedback (step count visible on watch, RMSSD logged on HRV4Training) outperform complex multi-step programs that require sustained executive function to maintain.

Right Now: Top Priorities

Derived from current data and what's already active — only gaps, no duplicates of established habits.

• Close the sleep duration gap — averaging 6h27m, target 7h 50min. Move in-bed time earlier from 21:20 if the gap persists after fragmentation is addressed first.
• Waist circumference re-measure (target ≤106 cm; visceral fat index 19.4 → <13 in 12 months). The eating and gym habits already in place are the right levers — measure monthly as the leading indicator.
• Anchor the daily meditation habit (baseline 2026-06-21) — RMSSD in HRV4Training every morning before coffee. This is the only new daily behaviour to add right now; adding more risks all of them collapsing.
• Rebuild aerobic capacity (noted as degraded in exercise log) — 20 min brisk walk on non-gym days is sufficient; no intensity until RMSSD trends >30 ms.
• Schedule blood panel before end of 2026 — declare creatine use, request eGFR + HbA1c + glucose. eGFR declining trend (78, from 121 in 2022) requires annual monitoring.

What's Going Well Recently

• Movement routine established and holding — gym 2× per week (Tue/Thu) at B12 Fitness and Salsa every Wednesday; three structured sessions without extra time cost.
• Blood pressure at last reading: 128/75 mmHg — within target (<130/80).
• Daily steps 8,923/day — at or above the 8,700-step personal baseline.
• Sleep fragmentation (WASO 44 min/night) — within the 23–50 min personal band.
• Respiratory rate 15.1/min — within the normal 13.5–15.2 band.
• Lipid panel healthy at last draw: LDL 78, HDL 65, ratio 2.4, cholesterol 160 — no statin territory despite family history.
• Meditation baseline locked in as of 2026-06-21 — first RMSSD readings available; autonomic tracking is now live.